4-[3-ethyl-5-(5-methylfuran-2-yl)pyrazol-1-yl]-2-nitro-N-(pyridin-3-ylmethyl)aniline | 1033439-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[3-ethyl-5-(5-methylfuran-2-yl)pyrazol-1-yl]-2-nitro-N-(pyridin-3-ylmethyl)aniline
• CAS: 1033439-62-1
• 化学式: C₂₂H₂₁N₅O₃
• 分子量: 403.44
• InChiKey: QTZPJORTXDVRPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[3-ethyl-5-(5-methylfuran-2-yl)pyrazol-1-yl]-2-nitro-N-(pyridin-3-ylmethyl)aniline 在 盐酸 、 tin 、 potassium peroxymonosulfate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[5-[3-Ethyl-5-(5-methyl-2-furyl)pyrazol-1-yl]-1-(3-pyridylmethyl)benzimidazol-2-yl]benzamide
  参考文献：
  名称：

  Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold

  摘要：

  A uHTS campaign led to the discovery of a 5-(5-furan-2-ylpyrazol-1-yl)-1H-benzimidazole series that inhibits assembly of HIV-1 capsid. Synthetic manipulations at N1, C2 and C16 positions improved the antiviral potency by a factor of 1000. The X-ray structure of 33 complexed with the capsid N-terminal domain allowed identification of major interactions between the inhibitor and the protein. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.034
• 作为产物：
  描述：

  4-氟-3-硝基苯胺 在 盐酸 、 溶剂黄146 、 三乙胺 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-[3-ethyl-5-(5-methylfuran-2-yl)pyrazol-1-yl]-2-nitro-N-(pyridin-3-ylmethyl)aniline
  参考文献：
  名称：

  Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold

  摘要：

  A uHTS campaign led to the discovery of a 5-(5-furan-2-ylpyrazol-1-yl)-1H-benzimidazole series that inhibits assembly of HIV-1 capsid. Synthetic manipulations at N1, C2 and C16 positions improved the antiviral potency by a factor of 1000. The X-ray structure of 33 complexed with the capsid N-terminal domain allowed identification of major interactions between the inhibitor and the protein. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.034

文献信息

• WO2008/67644
  申请人：——

  公开号：——

  公开（公告）日：——
• INHIBITORS OF HIV REPLICATION
  申请人：Yoakim Christiane

  公开号：US20100069353A1

  公开（公告）日：2010-03-18

  The present invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 and R 4 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.
• US8039638B2
  申请人：——

  公开号：US8039638B2

  公开（公告）日：2011-10-18
• [EN] INHIBITORS OF HIV REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIH
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2008067644A1

  公开（公告）日：2008-06-12

  [EN] The present invention relates to compounds of formula (I) wherein R¹, R², R³ and R⁴ are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.
  [FR] L'invention concerne des composés représentés par la formule (I) : dans laquelle R¹, R², R³ et R⁴ sont définis ici, qui sont utiles en tant qu'inhibiteurs de la réplication du VIH.